Vivos Therapeutics (VVOS) Change in Account Payables (2020 - 2026)
Vivos Therapeutics' (VVOS) quarterly Change in Account Payables came in at $318000.0 in Q1 2026, up 191.74% year-on-year from $109000.0 in Q1 2025, and up 175.0% on a QoQ basis from -$424000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Change in Account Payables (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of Change in Account Payables data on file, last reported at $318000.0 in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 191.74% year-over-year to $318000.0 in Q1 2026; TTM through Mar 2026 was $733000.0, a 156.69% increase from a year earlier, with the FY2025 full-year figure at $524000.0, up 150.0% from the prior year.
- Change in Account Payables for Q1 2026 stood at $318000.0, up from -$424000.0 in the prior quarter.
- Over the last five years, Change in Account Payables for VVOS reached as high as $767000.0 in Q4 2022 and fell as low as -$953000.0 in Q3 2024.
- Historically, Change in Account Payables has averaged $59941.2 across 5 years, with a median of $109000.0 in 2025.
- Across the five-year window, Change in Account Payables jumped 321.43% in 2024 and slumped 2027.27% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at $767000.0 in 2022, then declined by 19.69% to $616000.0 in 2023, then slumped by 96.43% to $22000.0 in 2024, then slumped by 2027.27% to -$424000.0 in 2025, then surged by 175.0% to $318000.0 in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $318000.0 in Q1 2026, -$424000.0 in Q4 2025, and $340000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -198.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 221.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Vivos Therapeutics | 3.62 Mn | 1.38 Mn | 3.06 Mn | 318,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 318,000.00 |
| Mar 31, 2026 | 318,000.00 |
| Dec 31, 2025 | -424,000.00 |
| Dec 31, 2025 | -424,000.00 |
| Sep 30, 2025 | 340,000.00 |
| Sep 30, 2025 | 340,000.00 |
| Jun 30, 2025 | 499,000.00 |
| Jun 30, 2025 | 499,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | -953,000.00 |
| Sep 30, 2024 | -953,000.00 |
| Jun 30, 2024 | -471,000.00 |
| Jun 30, 2024 | -471,000.00 |
| Mar 31, 2024 | 354,000.00 |
| Mar 31, 2024 | 354,000.00 |
| Dec 31, 2023 | 616,000.00 |
| Dec 31, 2023 | 616,000.00 |